Teva acquires migraine patch maker NuPathe
Teva has agreed to acquire pharmaceutical company NuPathe for $144 million.
The deal was made after NuPathe ended its merger agreement with Endo Health Solutions.
NuPathe develops drugs to treat neurological conditions. Its Zecuity product is a treatment for migraine that delivers medication through a patch worn on the skin.
Under the terms of the agreement, if Zecuity sales reach specified targets, NuPathe will receive additional payments from Teva.
Teva also announced that it will expand its portfolio of drugs that treat conditions affecting the central nervous system (CNS). It will have access to NuPathe’s proprietary technology including its transdermal delivery system.
Mike Derkacz, vice president and general manager of Teva’s CNS unit, said: “We believe that Zecuity is a great fit within our existing US CNS business unit, with near-term sales and significant commercial potential.”
He said that Zecuity’s delivery of active ingredient sumatriptan through the skin addresses the needs of patients who have migraine-related nausea by avoiding issues associated with taking drugs orally.
“At Teva, we will leverage our unique shared solutions infrastructure to support patient utilisation of this important new medicine for migraine sufferers,” he added.
NuPathe’s chief executive Armando Anido said that Teva is well-positioned to maximise Zecuity’s potential.
The transaction is expected to be completed in February 2014.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk